Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more
Amylyx Pharmaceuticals Inc (AMLX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.091x
Based on the latest financial reports, Amylyx Pharmaceuticals Inc (AMLX) has a cash flow conversion efficiency ratio of -0.091x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.90 Million) by net assets ($305.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Amylyx Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Amylyx Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Amylyx Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amylyx Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nine Entertainment Co. Holdings Limited
PINK:NNMTF
|
0.106x |
|
Tatung Co
TW:2371
|
-0.009x |
|
UMH Properties Inc
NYSE:UMH
|
0.025x |
|
Triumph Science & Technology Co Ltd
SHG:600552
|
-0.016x |
|
Suofeiya Home Collection Co Ltd
SHE:002572
|
-0.039x |
|
JVCKENWOOD Corporation
OTCGREY:JVCKF
|
0.075x |
|
Gemdale Corp
SHG:600383
|
-0.002x |
|
Tecnoglass Inc
NYSE:TGLS
|
0.052x |
Annual Cash Flow Conversion Efficiency for Amylyx Pharmaceuticals Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Amylyx Pharmaceuticals Inc from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.26 Million | $-123.34 Million | -0.404x | +60.29% |
| 2024-12-31 | $164.76 Million | $-167.65 Million | -1.017x | -3800.09% |
| 2023-12-31 | $433.43 Million | $11.92 Million | 0.027x | +105.21% |
| 2022-12-31 | $340.61 Million | $-179.87 Million | -0.528x | -206.73% |
| 2021-12-31 | $-151.17 Million | $-74.80 Million | 0.495x | -10.03% |
| 2020-12-31 | $-66.72 Million | $-36.70 Million | 0.550x | +30.49% |
| 2019-12-31 | $-25.36 Million | $-10.69 Million | 0.421x | -- |